KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EBITDA (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed EBITDA for 15 consecutive years, with -$3.9 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 118.39% to -$3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$62.3 million through Dec 2025, down 176.27% year-over-year, with the annual reading at -$62.3 million for FY2025, 176.27% down from the prior year.
  • EBITDA for Q4 2025 was -$3.9 million at Supernus Pharmaceuticals, up from -$60.2 million in the prior quarter.
  • The five-year high for EBITDA was $40.8 million in Q3 2024, with the low at -$60.2 million in Q3 2025.
  • Average EBITDA over 5 years is $7.3 million, with a median of $7.1 million recorded in 2021.
  • The sharpest move saw EBITDA crashed 255.01% in 2023, then surged 2249.1% in 2024.
  • Over 5 years, EBITDA stood at $6.1 million in 2021, then skyrocketed by 463.04% to $34.3 million in 2022, then tumbled by 102.9% to -$996000.0 in 2023, then soared by 2249.1% to $21.4 million in 2024, then crashed by 118.39% to -$3.9 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$3.9 million, -$60.2 million, and $12.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.